Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/31006
Title: Bone health assessment with dual energy X-ray absorptiometry in men with high-risk prostate carcinoma commencing adjuvant androgen deprivation therapy.
Austin Authors: Pan, Belinda;Aherne, Noel J;Shakespeare, Thomas P;Grossmann, Mathis ;Wong, Peter K
Affiliation: Department of Medicine, Coffs Harbour Health Campus, New South Wales, Australia
Department of Rheumatology, Westmead Hospital, Sydney, New South Wales, Australia
Faculty of Medicine and Health Sciences, Sydney University, Sydney, New South Wales, Australia
Department of Radiation Oncology, Mid-North Coast Cancer Institute, Coffs Harbour, New South Wales, Australia
School of Health and Human Sciences, Southern Cross University, New South Wales, Australia
Rural Clinical School Faculty of Medicine, University of New South Wales, New South Wales, Australia
The University of Melbourne, Melbourne, Victoria, Australia
Austin Health
Issue Date: 2022
Date: 2022
Publication information: Reports of Practical Oncology and Radiotherapy 2022; 27(4): 677-683
Abstract: Androgen deprivation therapy (ADT) is a key component of therapy for patients with high-risk prostate carcinoma, but it may be deleterious for bone health. We sought to determine the frequency of dual energy x-ray absorptiometry (DXA) scanning in patients commencing adjuvant ADT for treatment of high-risk prostate cancer at a large integrated regional cancer centre. The electronic medical records (EMR) of all patients with high-risk prostate carcinoma commenced on adjuvant ADT between January 1, 2016 and December 31, 2017 at the Mid-North Coast Cancer Institute, Coffs Harbour, Australia were reviewed. Patients commenced on neoadjuvant ADT and long-term suppressive ADT for metastatic disease were excluded. The following data were obtained: socio-demographic information, prostate cancer data, ADT details and DXA results. 188 men (mean age ± SD, 75.4 ± 7 years) were commenced on adjuvant ADT for a total duration (mean ± SD) of 23.4 ± 7 months. Most (n = 155/188, 82%) were commenced on leuprorelin acetate. While only 26/188 (14%) had a DXA scan performed prior to ADT, another 133 (71%) had a DXA scan at a median of 20 days (interquartile range 7-98), later. Of the 159 men with DXA readings, 76 (48%) were osteopaenic and 38 (24%) were osteoporotic by DXA criteria. A high level (85%) of DXA scanning in men commencing ADT for prostate cancer can be achieved at a regional centre. The high prevalence (72%) of low bone mass in our unselected cohort underscores the importance of routine DXA scanning to guide bone health management during ADT.
URI: https://ahro.austin.org.au/austinjspui/handle/1/31006
DOI: 10.5603/RPOR.a2022.0069
Journal: Reports of Practical Oncology and Radiotherapy : Journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology
PubMed URL: 36196418
ISSN: 1507-1367
Type: Journal Article
Subjects: DXA
androgen deprivation
bone density
osteoporosis
prostate cancer
Appears in Collections:Journal articles

Show full item record

Page view(s)

44
checked on Feb 16, 2025

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.